AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27835719 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine 4 g once daily for 12 weeks
Number of subjects: 121
Study 27835719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 24963662 — intervention group
Group type: EXPERIMENTAL
Intervention: P. vivax sporozoite-infected Anopheles mosquitoes (2-4 bites)
Number of subjects: 16
Study 22900524 — intervention group
Group type: EXPERIMENTAL
Intervention: Information Aid (IA)
Number of subjects: 45
Study 22900524 — intervention group
Group type: COMPARATOR
Intervention: Delayed access to IA (Control)
Number of subjects: 45
Study 21111093 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice, Control & Change curriculum
Number of subjects: 562
Study 21111093 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 562
Study 19074257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (anti-CTLA-4 monoclonal antibody)
Number of subjects: 15
Study 19074257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 15
Study 17162333 — intervention group
Group type: EXPERIMENTAL
Intervention: Solu Q10
Number of subjects: 54
Study 17162333 — intervention group
Group type: COMPARATOR
Intervention: Oily dispersions and crystalline CoQ10
Number of subjects: 54
Study 17162333 — intervention group
Group type: EXPERIMENTAL
Intervention: All formulations including Solu Q10
Number of subjects: 54
Study 12796021 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐19 mRNA-positive cells detected in peripheral blood after adjuvant chemotherapy
Number of subjects: 161
Study 12796021 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐19 mRNA-positive cells detected after adjuvant cyclophosphamide, methotrexate and 5‐fluorouracil (CMF)
Number of subjects: 161
Study 12796021 — intervention group
Group type: EXPERIMENTAL
Intervention: CK‐19 mRNA-positive cells detected in patients with four or more involved lymph nodes
Number of subjects: 161
Study 10824554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy of anticancer agents
Number of subjects: 0
Study 10824554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 0
Study 10824554 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of chemotherapy and thoracic irradiation
Number of subjects: 0
Study 10824554 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of anticancer agents with thoracic irradiation
Number of subjects: 0
Study 10824554 — intervention group
Group type: EXPERIMENTAL
Intervention: New agents demonstrating antitumor activity against lung cancer
Number of subjects: 0
Study 8648471 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hypotensive anesthesia (n = 25)
Number of subjects: 50
Study 8648471 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia with no attempt to deliberately reduce blood pressure (n = 25)
Number of subjects: 50
Study 8504648 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine (60 mg/500 mL)
Number of subjects: 239
Study 8504648 — intervention group
Group type: COMPARATOR
Intervention: No additive
Number of subjects: 239
Study 3032033 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with chest radiation therapy (Cyclophosphamide, methotrexate, lomustine, vincristine, adriamycin, procarbazine; chest irradiation to 40 Gy in 15 fractions over 3 weeks)
Number of subjects: 96
Study 3032033 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Cyclophosphamide, methotrexate, lomustine, vincristine, adriamycin, procarbazine)
Number of subjects: 96
Study 29380957 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIE)
Number of subjects: 5
Study 29380957 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MOD)
Number of subjects: 5
Study 29380957 — intervention group
Group type: COMPARATOR
Intervention: Sedentary Control (CON)
Number of subjects: 5
Study 26906747 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg primaquine
Number of subjects: 81
Study 26906747 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg primaquine
Number of subjects: 81
Study 26906747 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625 mg/kg primaquine
Number of subjects: 81
Study 26906747 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg/kg primaquine
Number of subjects: 81
Study 26906747 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg/kg primaquine)
Number of subjects: 81
Study 24039119 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO group
Number of subjects: 99
Study 24039119 — intervention group
Group type: COMPARATOR
Intervention: Clinical group
Number of subjects: 99
Study 22990510 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 23
Study 22990510 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study 19190547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg, 3 monthly injections)
Number of subjects: 37
Study 19190547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab plus PDT (0.5 mg, 3 monthly injections + 1 session of PDT)
Number of subjects: 37
Study 19190547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone plus PDT (4 mg, 1 injection + 1 session of PDT)
Number of subjects: 37
Study 17277240 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program (twice‐weekly treadmill assessments from 4 to 10 weeks postoperatively)
Number of subjects: 0
Study 17277240 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative and postoperative care (control group)
Number of subjects: 0
Study 17277240 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise program
Number of subjects: 0
Study 15621576 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 2
Study 15621576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 11895149 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (arginine, n‐3‐fatty acids, and nucleotides)
Number of subjects: 29
Study 9021436 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lansoprazole
Number of subjects: 24
Study 9021436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8198269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine (15 mg)
Number of subjects: 40
Study 8198269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (22.5 mg)
Number of subjects: 40
Study 3069457 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar
Number of subjects: 15
Study 29193553 — intervention group
Group type: EXPERIMENTAL
Intervention: AB-102 (novel topical solution containing a high concentration of a weak α1 agonist)
Number of subjects: 100
Study 29193553 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (previously used topical treatment)
Number of subjects: 100
Study 26692322 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intake (HI) group, consuming three cups (600 mL) of black tea per day
Number of subjects: 30
Study 26692322 — intervention group
Group type: COMPARATOR
Intervention: Low Intake (LI) group, administered 1 cup (200 mL) of black tea per day
Number of subjects: 30
Study 24240972 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 217
Study 24240972 — intervention group
Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 217
Study 23799688 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum doula support
Number of subjects: 39
Study 23799688 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer telephone support
Number of subjects: 39
Study 23799688 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 20506988 — intervention group
Group type: EXPERIMENTAL
Intervention: Visian Toric Implantable Collamer Lens (TICL)
Number of subjects: 88
Study 20506988 — intervention group
Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 88
Study 18400558 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-like chemotherapy alone
Number of subjects: 823
Study 18400558 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP-like chemotherapy with rituximab
Number of subjects: 823
Study 16809805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 100 mg on day 1
Number of subjects: 12
Study 16809805 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron 100 mg plus aprepitant 125 mg on day 1, aprepitant 80 mg on days 2-3
Number of subjects: 12
Study 12787235 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing Childbirth initiative (pilot scheme)
Number of subjects: 200
Study 12787235 — intervention group
Group type: COMPARATOR
Intervention: Traditional maternity care (control)
Number of subjects: 200
Study 11006067 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy (FS) screening
Number of subjects: 202
Study 11006067 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceiving fewer barriers to getting a FS
Number of subjects: 202
Study 11006067 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a physician recommend a FS
Number of subjects: 202
Study 11006067 — intervention group
Group type: EXPERIMENTAL
Intervention: Precontemplation stage of adoption
Number of subjects: 202
Study 11006067 — intervention group
Group type: EXPERIMENTAL
Intervention: FS beliefs, FS barriers, risk of developing colorectal cancer, worry about getting colorectal cancer, and physician recommendation to get a FS
Number of subjects: 202
Study 8797414 — intervention group
Group type: EXPERIMENTAL
Intervention: Saralasin, 5 micrograms/kg/min
Number of subjects: 8
Study 8797414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1497392 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin with warfarin
Number of subjects: 199
Study 1497392 — intervention group
Group type: COMPARATOR
Intervention: Heparin only
Number of subjects: 199
Study 6736589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's voice
Number of subjects: 25
Study 6736589 — intervention group
Group type: COMPARATOR
Intervention: Unknown voices
Number of subjects: 25
Study 6736589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's voice (after excluding cold voices)
Number of subjects: 25
Study 6736589 — intervention group
Group type: COMPARATOR
Intervention: Other women (after excluding cold voices)
Number of subjects: 25
Study 31170332 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating sclerostin levels (genetic instrument derived from SNPs)
Number of subjects: 426824
Study 29651784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for CRF
Number of subjects: 81
Study 29651784 — intervention group
Group type: COMPARATOR
Intervention: Population controls
Number of subjects: 81
Study 26815179 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3) 300 mg · kg(‐1) in 450 ml of flavored water
Number of subjects: 11
Study 26815179 — intervention group
Group type: COMPARATOR
Intervention: Control (no drink)
Number of subjects: 11
Study 26815179 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 270 mg · kg(‐1) body mass)
Number of subjects: 11
Study 24440102 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (IOL)
Number of subjects: 30
Study 24440102 — intervention group
Group type: COMPARATOR
Intervention: Peripheral corneal relaxing incisions (PCRIs)
Number of subjects: 30
Study 22157131 — intervention group
Group type: EXPERIMENTAL
Intervention: SAAF-T program (family-centered preventive intervention)
Number of subjects: 502
Study 22157131 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 502
Study 20698991 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical device treatment
Number of subjects: 0
Study 20698991 — intervention group
Group type: COMPARATOR
Intervention: Control group (identical foot-worn platform without biomechanical elements)
Number of subjects: 0
Study 17576843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevirimat (BVM) 25 mg
Number of subjects: 14
Study 17576843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevirimat (BVM) 50 mg
Number of subjects: 14
Study 17576843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevirimat (BVM) 100 mg
Number of subjects: 14
Study 17576843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevirimat (BVM) 250 mg
Number of subjects: 14
Study 17576843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 16386155 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day training program of walking 1800 feet per day with instructions to take long steps
Number of subjects: 16
Study 16386155 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16
Study 12006727 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary treatment (herbal remedy Sinupret and homeopathic remedy Cinnabaris 3X)
Number of subjects: 63
Study 12006727 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (antibiotics, secretolytics, symptomimetics)
Number of subjects: 63
Study 10541897 — intervention group
Group type: EXPERIMENTAL
Intervention: One-site approach (superior tunnel phacoemulsification under a scleral flap with subsequent trabeculectomy)
Number of subjects: 50
Study 10541897 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-site approach (temporal corneal phacoemulsification combined with a separate-incision superior trabeculectomy)
Number of subjects: 50
Study 10541897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study 7546837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy with autologous bone marrow stem cell support
Number of subjects: 0
Study 7546837 — intervention group
Group type: COMPARATOR
Intervention: Conventional doses of polychemotherapy
Number of subjects: 0
Study 2182959 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg p.o.)
Number of subjects: 10
Study 2182959 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg p.o.) + Naloxone (2.8 mg i.v. in 5 h)
Number of subjects: 10
Study 2182959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral and i.v.)
Number of subjects: 10
Study 6456068 — intervention group
Group type: EXPERIMENTAL
Intervention: Mezlocillin (1.5 gm) administered intramuscularly every six hours for seven days
Number of subjects: 60
Study 6456068 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin (2 gm) administered intramuscularly every six hours for seven days
Number of subjects: 60
Study 31688089 — intervention group
Group type: EXPERIMENTAL
Intervention: CAncer Pain management support Program
Number of subjects: 94
Study 31689581 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional advice and seedlings of Calliandra calothyrsus and Sesbania sesban
Number of subjects: 155
Study 31689581 — intervention group
Group type: EXPERIMENTAL
Intervention: Calliandra or Sesbania supplementation
Number of subjects: 155
Study 31689581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Calliandra or Sesbania supplementation)
Number of subjects: 155
Study 28790162 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening examinations including laboratory assessments and various imaging modalities (e.g. CT, MRI, scintigraphy and EUS) for MEN1 patients.
Number of subjects: 0
Study 28790162 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of different and new imaging methods regarding their sensitivity and utility in MEN1 patients.
Number of subjects: 0
Study 25849094 — intervention group
Group type: EXPERIMENTAL
Intervention: Audience Response System (ARS)
Number of subjects: 100
Study 25849094 — intervention group
Group type: COMPARATOR
Intervention: Non-Audience Response System (non-ARS)
Number of subjects: 100
Study 22898358 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS single‐sided gel delivery
Number of subjects: 3
Study 22898358 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS double‐sided gel delivery
Number of subjects: 3
Study 22898358 — intervention group
Group type: COMPARATOR
Intervention: Vaginal applicator
Number of subjects: 3
Study 22295535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg over 10 min, then 0.4 microg/(kg x h) for 30 min)
Number of subjects: 100
Study 22295535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 100
Study 19098010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle brachial pressure index (ABPI) over 0.6
Number of subjects: 133
Study 19098010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) measurement
Number of subjects: 133
Study 16981917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (n=52)
Number of subjects: 100
Study 16981917 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber ICD (n=48)
Number of subjects: 100
Study 16981917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (n=52) with frequent ventricular pacing (≥35%)
Number of subjects: 100
Study 16981917 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICD (n=52) with low ventricular pacing (<35%)
Number of subjects: 100
Study 15018377 — intervention group
Group type: EXPERIMENTAL
Intervention: Before and After diet advertisement
Number of subjects: 59
Study 15018377 — intervention group
Group type: COMPARATOR
Intervention: Before Picture Only
Number of subjects: 59
Study 15018377 — intervention group
Group type: COMPARATOR
Intervention: After Picture Only
Number of subjects: 59
Study 10835457 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyography-triggered neuromuscular electrical stimulation
Number of subjects: 11
Study 10835457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no external assistance for wrist and finger extension)
Number of subjects: 11
Study 9357880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 30
Study 9357880 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 30
Study 8256088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (multiple doses)
Number of subjects: 0
Study 8256088 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (single dose)
Number of subjects: 0
Study 8256088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3517694 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 303
Study 3517694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 31251888 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 water
Number of subjects: 159
Study 31251888 — intervention group
Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 159
Study 30013436 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron plus dexamethasone (group PD)
Number of subjects: 202
Study 30013436 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron alone (group P)
Number of subjects: 202
Study 27015909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release dexamfetamine (60 mg/day)
Number of subjects: 73
Study 27015909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 27015909 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release dexamfetamine
Number of subjects: 73
Study 24864199 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR; n = 18)
Number of subjects: 33
Study 24864199 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction with aerobic exercise (CR + Ex; n = 15)
Number of subjects: 33
Study 24864199 — intervention group
Group type: COMPARATOR
Intervention: Control group (CR)
Number of subjects: 33
Study 22325170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 160/80 mg
Number of subjects: 90
Study 22325170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80/40 mg
Number of subjects: 90
Study 22325170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22325170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (maintenance 40 mg every other week)
Number of subjects: 90
Study 22325170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maintenance)
Number of subjects: 90
Study 22325170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 90
Study 22325170 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab and Placebo
Number of subjects: 90
Study 20396721 — intervention group
Group type: EXPERIMENTAL
Intervention: artrofoon
Number of subjects: 0
Study 17240440 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula
Number of subjects: 2252
Study 17240440 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed whey formula
Number of subjects: 2252
Study 17240440 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk formula
Number of subjects: 2252
Study 15020173 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, motivational outreach
Number of subjects: 254
Study 15020173 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 254
Study 12059886 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil-ropivacaine infusion with epinephrine (n=32)
Number of subjects: 61
Study 12059886 — intervention group
Group type: COMPARATOR
Intervention: Epidural sufentanil-ropivacaine infusion without epinephrine (n=29)
Number of subjects: 61
Study 9822001 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming (normothermia group)
Number of subjects: 60
Study 9822001 — intervention group
Group type: COMPARATOR
Intervention: Routine care (hypothermia group)
Number of subjects: 60
Study 8126039 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive epidural anesthesia, external pneumatic-compression boots, and aspirin (Group I)
Number of subjects: 231
Study 8126039 — intervention group
Group type: COMPARATOR
Intervention: Hypotensive epidural anesthesia and aspirin (Group II)
Number of subjects: 231
Study 2531270 — intervention group
Group type: EXPERIMENTAL
Intervention: SPG plus tegafur‐‐F method or 5‐FU combined with MMC‐‐MF method
Number of subjects: 0
Study 2531270 — intervention group
Group type: EXPERIMENTAL
Intervention: SPG administered intramuscularly 40mg/week
Number of subjects: 0
Study 2531270 — intervention group
Group type: COMPARATOR
Intervention: Control group (chemotherapy only)
Number of subjects: 0